Xintela Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
XINT
- Share Price
-
$0.01
- (As of Friday Closing)
Xintela General Information
Description
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
Contact Information
Website
www.xintela.seCorporate Office
- Medicon Village
- 223 81 Lund
- Sweden
Corporate Office
- Medicon Village
- 223 81 Lund
- Sweden
Xintela Stock Performance
As of 13-Nov-2026, Xintela’s stock price is $0.01. Its current market cap is $12M with 861M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.01 | $0.01 | $0.01 - $0.04 | $12M | 861M | 235K |
Xintela Financials Summary
As of 30-Jun-2026, Xintela has a trailing 12-month revenue of $323K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 16,809 | 21,378 | 19,841 | 14,204 |
| Revenue | 323 | 232 | 399 | 7 |
| EBITDA | (4,850) | (4,690) | (3,678) | (5,031) |
| Net Income | (5,096) | (4,943) | (3,706) | (5,088) |
| Total Assets | 3,612 | 3,154 | 2,248 | 1,841 |
| Total Debt | 3,087 | 2,173 | 1,858 | 0 |
Xintela Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xintela Patents
Xintela Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022277806-A1 | Mesenchymal stem cells for use in the treatment of skin defects | Active | 20-May-2021 | ||
| AU-2022277806-B2 | Mesenchymal stem cells for use in the treatment of skin defects | Active | 20-May-2021 | ||
| CA-3218101-A1 | Mesenchymal stem cells for use in the treatment of skin defects | Pending | 20-May-2021 | ||
| EP-4340854-A1 | Mesenchymal stem cells for use in the treatment of skin defects | Pending | 20-May-2021 | ||
| US-12599633-B2 | Mesenchymal stem cells for use in the treatment of skin defects | Active | 20-May-2021 | A61K35/28 |
Xintela Signals
Xintela Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xintela ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Xintela Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Targinta | Lund, Sweden | 2018 |
Xintela FAQs
-
When was Xintela founded?
Xintela was founded in 2009.
-
Where is Xintela headquartered?
Xintela is headquartered in Lund, Sweden.
-
What is the size of Xintela?
Xintela has 11 total employees.
-
What industry is Xintela in?
Xintela’s primary industry is Drug Discovery.
-
Is Xintela a private or public company?
Xintela is a Public company.
-
What is Xintela’s stock symbol?
The ticker symbol for Xintela is XINT.
-
What is the current stock price of Xintela?
As of 13-Nov-2026 the stock price of Xintela is $0.01.
-
What is the current market cap of Xintela?
The current market capitalization of Xintela is $12M.
-
What is Xintela’s current revenue?
The trailing twelve month revenue for Xintela is $323K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process